JP2003524623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003524623A5 JP2003524623A5 JP2000610472A JP2000610472A JP2003524623A5 JP 2003524623 A5 JP2003524623 A5 JP 2003524623A5 JP 2000610472 A JP2000610472 A JP 2000610472A JP 2000610472 A JP2000610472 A JP 2000610472A JP 2003524623 A5 JP2003524623 A5 JP 2003524623A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- alkyl
- hydrogen
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- -1 Methylenedioxy group Chemical group 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 式I:
【化1】
式中:
XはCH2または酸素であり;
R1は水素またはアルキルであり;そして
R2、R3、R4及びR5は独立して水素またはアルキルであり、そしてXがCH2である場合には、R4及びR5はベンゼン環を形成するように連結されたアルケン基であることができ、そしてXが酸素である場合には、R2とR3及び/またはR4とR5は一緒に以下の式(II):
【化2】
式中、
R6及びR7は同じまたは異なり、水素またはアルキルであり、そしてシクロペンチルまたはシクロヘキシル環を形成するように連結される、
のメチレンジオキシ基であることができる、
の化合物を有効成分として含んでなる哺乳類における血液グルコースレベルを下げるための製薬学的製剤。
【請求項2】 式Iの化合物がトピラメートである請求項1記載の製剤。
【請求項3】 式Iの化合物が約100〜400mg投与される請求項1記載の製剤。
[Claims]
1. Formula I:
Embedded image
Where:
X is CHTwoOr oxygen;
R1Is hydrogen or alkyl; and
RTwo, RThree, RFourAnd RFiveIs independently hydrogen or alkyl, and X is CHTwo, Then RFourAnd RFiveCan be an alkene group linked to form a benzene ring, and when X is oxygen, RTwoAnd RThreeAnd / or RFourAnd RFiveTogether with the following formula (II):
Embedded image
Where:
R6And R7Are the same or different and are hydrogen or alkyl, and are linked to form a cyclopentyl or cyclohexyl ring,
Methylenedioxy group of
Compound ofComprising as an active ingredientDecrease blood glucose levels in mammalsPharmaceutical preparations for.
2. The compound according to claim 1, wherein the compound of formula I is topiramate.The described formulation.
(3) The compound of formula IAbout 100-400mg administrationBe doneClaim 1The described formulation.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12839899P | 1999-04-08 | 1999-04-08 | |
US60/128,398 | 1999-04-08 | ||
US09/538,803 | 2000-03-30 | ||
PCT/US2000/008404 WO2000061139A1 (en) | 1999-04-08 | 2000-03-30 | Anticonvulsant derivatives useful in reducing blood glucose levels |
US09/538,803 US6362220B1 (en) | 1999-04-08 | 2000-03-30 | Anticonvulsant derivatives useful in reducing blood glucose levels |
Publications (4)
Publication Number | Publication Date |
---|---|
JP2003524623A JP2003524623A (en) | 2003-08-19 |
JP2003524623A6 JP2003524623A6 (en) | 2006-12-14 |
JP2003524623A5 true JP2003524623A5 (en) | 2007-02-15 |
JP4709392B2 JP4709392B2 (en) | 2011-06-22 |
Family
ID=26826545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000610472A Expired - Lifetime JP4709392B2 (en) | 1999-04-08 | 2000-03-30 | Anticonvulsant derivatives useful for lowering blood glucose levels |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4709392B2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1106193C (en) * | 1996-06-28 | 2003-04-23 | 奥索·麦克尼尔药品公司 | Anticonvulsant sulfamate derivs. useful in treating obesity |
-
2000
- 2000-03-30 JP JP2000610472A patent/JP4709392B2/en not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003521471A5 (en) | ||
JP2004505004A5 (en) | ||
JP2002541199A5 (en) | ||
ATE226815T1 (en) | MANUFACTURING OF MEDICINAL PRODUCTS | |
JP2003501474A5 (en) | ||
RU2003100076A (en) | ANTI-CURRENT DERIVATIVES USED TO PREVENT DEVELOPMENT OF DIABETES AND SYNDROME X | |
CA2399208A1 (en) | Nucleoside analogs with carboxamidine modified monocyclic base | |
Xiang et al. | Transbuccal delivery of 2′, 3′-dideoxycytidine: in vitro permeation study and histological investigation | |
AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
EE04800B1 (en) | Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form | |
CA2301017A1 (en) | Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds | |
GEP20043315B (en) | Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof | |
EP1283054A4 (en) | Drugs for complications of diabetes and neuropathy and utilization thereof | |
JP2003500442A5 (en) | ||
JP2003506416A5 (en) | ||
HUP0500558A2 (en) | Low dose entecavir formulation and process for its preparation | |
DK0830145T3 (en) | Formulations comprising leflunomide | |
JP2002519425A5 (en) | ||
YU17700A (en) | Oral copositions of levosimendan | |
KR970706792A (en) | The lyophilizate of lipid complex of water insoluble camptothecins of water-insoluble camptothecin. | |
JP2002536328A5 (en) | ||
RU97107856A (en) | LIOPHYLIZATE OF THE LIPID COMPLEX OF WATER-INSOLVED CAMPOTECINE | |
KR890004701A (en) | Antiretrovirus castanospermine ester | |
JP2004512362A (en) | Oral self-emulsifying formulation of pyranone protease inhibitor | |
KR830002510A (en) | Composition consisting of biologically active compound and hydroxyalkyl starch |